Elixir Medical Marketing

01/08/2020

The value of scientific innovation!

The drop was largely credited to a decline in lung cancer deaths due to advances in treatments, among other factors, the American Cancer Society said.

08/06/2019

This is very bad for Novartis, and gives pharma a big black eye in general. Integrity is the foundation of scientific advancement and we must uphold the strictest of standards.

In a statement, the agency said it will "use its full authorities to take action, if appropriate, which may include civil or criminal penalties."

07/17/2019

Today marks the 1 year anniversary of Elixir! We're thrilled to have had the success we've achieved and to be providing expert services to our clients! Onward and upward!

07/09/2019

Pharma is still under the cross hairs, but this "sticker price" rule was meaningless as far as it relates to what people actually pay for pharmaceuticals

The federal district court sided with drugmakers, which argued the government overstepped its authority in forcing price transparency in advertisements.

05/12/2019

Using viruses to fight bacteria. Great to see the modern refinement of an old experimental approach that is helping patients who have few other options

While phage experts were excited by the work, clinicians wonder to what extent it can be scaled up to combat the global crisis of antibiotic resistance.

04/25/2019

Very interesting approach on using immune checkpoint inhibition as a treatment for progressive multifocal leukoencephalopathy (PML). Keytruda (pembrolizumab) demonstrated efficacy in improving or stabilizing PML, lowering JC viral load, and enhancing anti-JC virus CD4 and CD8 T-cell activity.

This is good news for patients who receive potent immunosuppresive or immunomodulatory therapies (eg, Tysabri for multiple sclerosis) and are at risk for PML.

It would be interesting to look at responders vs nonresponders and determine if there are specific patient or disease factors that correlate with Keytruda responsiveness.

https://www.nejm.org/doi/full/10.1056/NEJMoa1815039

Original Article from The New England Journal of Medicine — Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy

02/26/2019

New real-world study demonstrates early intensive treatment of MS improves disability outcomes over 5 years. It's time to get past the now-25-year-old first-line therapies for the innovative high-efficacy disease-modifying therapies. JAMA Neurology

02/25/2019

Another big acquisition and big play for advancing gene therapy!

It's the latest evidence of pharma's growing appetite to expand in a field where Spark has been a leader with development of its approved treatment Luxturna.

01/03/2019

Whoa! Big merger in the works!

Combining Bristol-Myers immunotherapy business with Celgene's blood cancer franchise would create a top oncology company in the industry's hottest field.

10/16/2018

October 16, 2018: Elixir Medical Marketing posted an article on LinkedIn

10/04/2018

Big week for immunology! Sir Gregory Winter wins the 2018 Nobel Prize in Chemistry for pioneering research on phage display to push affinity maturation of antibodies, which is fundamental to how therapeutic monoclonoal antibodies have been developed

“Sir Gregory Winter, awarded the in Chemistry, has used phage display to produce new pharmaceuticals. Today phage display has produced antibodies that can neutralise toxins, counteract autoimmune diseases and cure metastatic cancer.”

10/01/2018

The 2018 Nobel Prize in Physiology or Medicine has been awarded to American Dr James Allison and Japan's Dr Tasuku Honjo for their pioneering work leading to the development cancer immunotherapies that "take the brakes off" the immune system and stimulate the patient's own immune system to kill tumor cells. These immune checkpoint inhibitors are now revolutionizing the treatment of cancer and saving millions of lives.

I met Dr Allison years ago and could not think of someone more deserving.